Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study

Giulia Lanzolla1 · Francesca Menconi1 · Francesca Nicoli1 · Chiara Posarelli2 · Maria Novella Maglionico2 · Michele Figus2 · Marco Nardi2 · Claudio Marcocci1 · Michele Marinò1

Received: 2 February 2021 / Accepted: 25 February 2021 / Published online: 12 April 2021
© The Author(s) 2021

Abstract

Objective Graves’ orbitopathy (GO) reflects an autoimmune response against antigens expressed by the thyroid and orbital tissues. Elimination of thyroid antigens may be beneficial for GO. Total thyroid ablation (TTA) [thyroidectomy (Tx), followed by 30 mCi of radioiodine] was shown to exert a beneficial effect on GO following intravenous glucocorticoids (ivGC) compared with Tx alone. Here, we investigated retrospectively whether TTA performed with a 15 mCi of radioiodine still maintains advantages over Tx.

Methods Thirty-two subjects, 13 treated with TTA (performed with 15 mCi of radioiodine) and 19 with Tx alone, all with moderately severe, active GO, treated with ivGC, were studied. The primary objective was the outcome of GO at 24 weeks based on a composite evaluation.

Results The two groups did not differ at baseline in terms of sex, age, smoking habits, TSH, anti-TSH receptor autoantibodies, GO duration and eye features. The proportion of GO responders at 24 weeks was greater in the TTA (61.5%) than in the Tx group (26.3%, \(P = 0.046\)). In contrast, GO outcome at 48 weeks did not differ between the two groups (69.2% vs 52.6% of responder in TTA and Tx group, respectively). The outcome of the individual GO features did not differ between the two groups both a 24 and 48 months.

Conclusions The advantage of total thyroid ablation seems to be a more rapid response for GO to ivGC treatment. Prospective, randomized studies in a larger number of subjects are needed to confirm our findings.

Keywords Graves’ disease · Graves’ orbitopathy · Ablation · Radioiodine · Thyroid · Autoimmunity

Introduction

Graves’ orbitopathy (GO) is believed to be due to an autoimmune reaction against antigens expressed by thyroid epithelial cells and orbital tissues, being the TSH receptor (TSH-R) the most suitable candidate, and the insulin-like growth factor-I receptor a putative one [1–3]. Based on this hypothesis, it has been postulated that elimination of thyroid antigens may be beneficial for GO [4]. A few studies have indeed shown a beneficial effect of total thyroid ablation (TTA), achieved by near-total thyroidectomy (Tx), followed by radioiodine given as a fixed activity of 30 mCi [5, 6]. In a recent, pilot, prospective study, we showed that a sufficient extent of thyroid ablation, assessed as recombinant human TSH (rhTSH)-stimulated Tg, can be achieved with a radioiodine activity of 15 mCi upon rhTSH stimulation [7]. Therefore, over the last few years, we treated a few thyroidectomized patients with moderately severe and active GO with 15 mCi of radioiodine, followed by intravenous glucocorticoids (ivGC), the usual treatment for this obnoxious eye disease [8]. In two previous, randomized clinical trials in which GO patients who underwent ivGC following TTA (performed with a 30 mCi activity after surgery) or Tx alone were compared, TTA resulted in a beneficial effect on GO [5, 6]. Thus, the aim of the present study was to investigate retrospectively whether TTA performed with a 15 mCi activity of radioiodine still maintains advantages over Tx.
alone following ivGC. The results show a better outcome of GO at 24 weeks, assessed using a composite evaluation, in patients treated with TTA, in confirmation of the validity of this therapeutic approach.

**Subjects and methods**

**Study design**

The study was aimed at investigating retrospectively the outcome of moderately severe, active GO following ivGC, based on thyroid treatment, namely TTA vs Tx alone. The study entailed the inclusion of all consecutive patients with moderately severe, active GO who had undergone ivGC treatment following either Tx or TTA, the latter performed with 15 mCi of radioiodine after thyroidectomy, over a period of 2 consecutive years.

**Setting**

The study was performed in a tertiary referral center, namely the University Hospital of Pisa. A database search was conducted to identify patients with moderately severe GO treated with ivGC following either Tx or TTA from January 1st 2018 till December 31st 2019. Patients were included by means of consecutive sampling. The inclusion and exclusion criteria are reported below. The data were recorded in a database. The following database validation procedures were employed: allowed character checks, batch totals, missing records check, cardinality check, digits check, consistency check, control totals, cross-system consistency check, data type check, hash totals, logic check, presence check, range check, spelling and grammar check, and uniqueness check.

**Participants**

Inclusion criteria were: (1) male and female patients aged 18–85 years; (2) a diagnosis of Graves’ hyperthyroidism (GH) before thyroidectomy, based on a history of hyperthyroidism, associated with previous or present detectable serum autoantibodies against the TSH-R (TRAbs); (3) near-total thyroidectomy; (4) a diagnosis of moderately severe, active GO, based on the presence of at least one of the following eye features, associated with a clinical activity score (CAS) ≥ 3/7: exophthalmometry ≥ 22 mm; eyelid aperture ≥ 13 mm; (iii) presence of inconstant or constant diplopia; (5) written, signed informed consent to data use.

Exclusion criteria were: (1) treatment with GC or any immunosuppressive medication in the preceding 3 months; (2) presence of optic neuropathy, according to previously established criteria [8]; (3) lack of informed consent.

A total of 32 subjects (10 men and 22 women, age 47.5 ± 10.5 years, range 19–64 years) who satisfied the inclusion criteria and evaded the exclusion criteria were recruited, of whom 13 had been treated with TTA and 19 with Tx alone. They were enrolled in the study and evaluated at baseline and then at 24 and 48 weeks. Being a retrospective study, no ethical approval was required.

**Outcomes**

The primary objective of the study was the overall outcome of GO at 24 weeks based on a composite evaluation. Patients were considered as responders when at least two of the following criteria were fulfilled, without worsening of the other criteria: (1) reduction in proptosis ≥ 2 mm in at least one eye, with no increase ≥ 2 mm in the other eye; (2) reduction of CAS ≥ 2/7 points; (3) reduction in eyelid aperture ≥ 2 mm in at least one eye, with no increase ≥ 2 mm in the other eye; (4) disappearance or improvement (change of degree from constant to inconstant or intermittent, or from inconstant to intermittent) of diplopia. In all other cases, patients were considered as non-responders.

The secondary outcomes were: (1) the overall outcome of GO at 48 weeks; (2) the outcome of proptosis at 24 and 48 weeks, namely a reduction ≥ 2 mm in at least one eye, with no increase ≥ 2 mm in the other eye; 2) the outcome of CAS at 24 and 48 weeks, namely a reduction ≥ 2/7 points; (3) the outcome of eyelid aperture at 24 and 48 weeks, namely a reduction ≥ 2 mm in at least one eye, with no increase ≥ 2 mm in the other eye; (4) the outcome of diplopia at 24 and 48 weeks, namely its disappearance or change in degree from constant to inconstant or intermittent, or from inconstant to intermittent.

**Sources of data and measurements**

An ophthalmological evaluation was performed in all patients, including: (1) exophthalmometry; (2) measurement of eyelid aperture; (3) evaluation of CAS; (4) assessment of diplopia; (5) assessment of the corneal status; (6) examination of the fundi; and (7) measurement of visual acuity. The following blood tests were performed in all subjects: (1) FT4, FT3 (Vitros Immunodiagnostics, Raritan, NJ); (2) TSH (Immulite 2000, Siemens Healthcare, Gwynedd, UK); and (3) anti-TSH receptor autoantibodies (TRAbs) (Brahms, Berlin, Germany).

**Interventions**

All patients had been subjected to near-total thyroidectomy. Ablation was performed in 13 patients with 15 mCi of 131I upon rhTSH stimulation. A single dose of 0.9 mg was administered intramuscularly 48 and 24 h before
radioiodine. All patients were on LT4 therapy at replacement doses. All patients were treated with ivGC after thyroid treatment. Patients were given 1 iv infusion/week of methylprednisolone for a total of 12 infusions. The dose was 500 mg for the first six infusions and 250 mg for the last six infusions, for a cumulative dose of 4.5 g, as described previously [7]. No major side effects of GC were observed.

Statistical power

As reported above, we identified 32 patients who fulfilled the inclusion criteria and evaded the exclusion criteria during the indicated period. Being a retrospective study over a limited period of time, a sample size could not be calculated. Instead, based on the results of the primary outcome measure (see below), we calculated the post-hoc statistical power, which resulted to be 47.6% for a $P$ value $\leq 0.05$.

Quantitative variables

Continuous variables with a normal distribution, which was assessed using the Shapiro–Wilks test, are presented as mean $\pm$ SD. The remaining continuous variables are presented as median and IQR.

### Table 1 Features of patients with Graves’ Orbitopathy (GO) at baseline

| Feature                        | TTA                        | TX                        | $P$  |
|--------------------------------|----------------------------|----------------------------|------|
| Gender                         | Males: 2; Females: 11      | Males: 8; Females: 11     | 0.109|
| Age (yr)                       | 48 ± 9.7 (range 26–60)     | 47.2 ± 11.3 (range 19–64) | NS   |
| Smoking habits                 | Non-smokers 6              | Non-smokers 7             | 0.888|
|                                | Ex smokers: 2              | Ex smokers: 3             |      |
|                                | Current smokers: 5         | Current smokers: 9        |      |
| TSH (mU/L; NV 0.4–4)           | 1.1 (IQR 0.3–3.5)          | 2.0 (IQR 0.2–4.5)         | NS   |
| TRAbs (IU/L; NV < 1.5)         | 9.3 (IQR 2.6–14.2)         | 4.4 (IQR 2.5–7.5)         | NS   |
| GO duration (mo.)              | 15 (IQR 15–18)             | 13 (IQR 9–16.5)           | NS   |
| Time between TX and baseline evaluation (mo.) | 4 (IQR 4–6) | 4 (IQR 2.5–7.5) | NS   |
| Exophthalmometry (most affected eye) (mm) | 24.7 ± 2.1 (range 19–28) | 24.9 ± 3.6 (range 19–35) | NS   |
| Clinical Activity Score (points) | 4.6 ± 1.3 (range 3–7) | 4.2 ± 0.9 (range 3–6) | NS   |
| Double vision                  | Absent: 2                  | Absent: 6                 | NS   |
|                                | Intermittent: 1            | Intermittent: 1           |      |
|                                | Inconstant: 4              | Inconstant: 9             |      |
|                                | Constant: 6                | Constant: 3               |      |
| Best corrected visual acuity (most affected eye) (decimals; NV 1.0) | 0.9 ± 0.02 (range 0.9–1.0) | 1 ± 0 (range 10–10) | NS   |

TTA total thyroid ablation (thyroidectomy followed by 15 mCi of radioiodine), Tx thyroidectomy, TRAbs serum anti-TSH-receptor autoantibodies, NV normal values

Continuous variables are reported as mean $\pm$ SD or median and IQR

$P$ values were obtained by Chi square (categorical variables), ANOVA with Bonferroni’s correction (continuous variables with normal distribution), or Mann–Whitney (continuous variables with non-normal distribution)

Statistical analyses

When appropriate, the following tests were performed: (1) ANOVA with Bonferroni’s correction; (2) Mann–Whitney; and (3) Chi-square.

Results

Features of patients

The main demographic and clinical variables of the patient population at baseline are reported in Table 1. The two groups did not differ in terms of gender, age, smoking habits, TSH and TRAbs concentrations at baseline, GO duration and time between Tx and baseline evaluation. Likewise, the eye features of the two groups were similar, having both a moderately severe, active GO.

Outcome measures

As shown in Fig. 1, using a composite evaluation, the proportion of GO responders to ivGC at 24 weeks was greater in the TTA (61.5%) than in the Tx group (26.3%), with a statistically significant difference ($P=0.046$), thereby fulfilling the primary outcome of the study. In contrast, GO outcome at 48 weeks did not differ significantly between
the two groups, in spite of a slightly greater proportion of responders in the TTA group (69.2% vs 52.6% in the Tx group). As shown in Fig. 2, the outcome of the individual GO features did not differ between patients who underwent TTA and those who underwent Tx, in spite of a tendency towards a better response to treatment in the TTA group in terms of diplopia (Fig. 2c), which did not reach statistical significance, possibly because of the relatively limited number of subjects and the consequent relatively low statistical power.

Discussion

The optimal treatment of thyroid dysfunction in patients with GO as well as its impact on the eye disease remain to be established [8]. Whereas some prefer a conservative approach based on the prolonged use of anti-thyroid medications, other have proposed an ablative approach with Tx, radioiodine or both, based on the idea that GO reflects an autoimmune response against antigens expressed both in the thyroid and in fibroadipose orbital tissues [1, 4, 8]. TTA, performed with Tx followed by radioiodine, was first proposed by Catz and Perzik [9], and two retrospective studies showed an improvement of GO following this therapeutic approach [10, 11]. Two

![Fig. 1](image1)

Overall outcome of Graves’ Orbitopathy (GO) (proportion of responders) at 24 and 48 weeks, following intravenous glucocorticoids, in patients with moderately severe, active GO treated with total thyroid ablation (TTA, thyroidectomy followed by 15 mCi of radioiodine), or thyroidectomy alone (Tx). Patients were considered as responders when at least two of the following criteria were fulfilled, without worsening of the other criteria: (1) reduction in proptosis ≥ 2 mm in at least one eye, with no increase ≥ 2 mm in the other eye; (2) reduction of Clinical Activity Score ≥ 2/7 points; (3) reduction in eyelid aperture ≥ 2 mm in at least one eye, with no increase ≥ 2 mm in the other eye; (4) disappearance or improvement (change of degree from constant to inconstant or intermittent, or from inconstant to intermittent) of diplopia. P values were obtained by Chi-square

![Fig. 2](image2)

Outcome of individual eye features of Graves’ Orbitopathy (GO) (proportion of responders) at 24 and 48 weeks, following intravenous glucocorticoids, in patients with moderately severe, active GO treated with total thyroid ablation (TTA, thyroidectomy followed by 15 mCi of radioiodine), or thyroidectomy alone (Tx). a Proptosis. Patients with a reduction ≥ 2 mm in at least one eye and with no increase ≥ 2 mm in the other eye were considered as responder; b Clinical Activity Score. Patients with a reduction ≥ 2/7 points were considered as responder; c Diplopia. Patients with disappearance or improvement (change of degree from constant to inconstant or intermittent, or from inconstant to intermittent) were considered as responders; d Eyelid aperture. Patients with a reduction ≥ 2 mm in at least one eye and with no increase ≥ 2 mm in the other eye were considered as responders. P values were obtained by Chi-square
randomized clinical trials conducted in patients with moderately severe, active GO treated with ivGC following Tx alone or TTA, the latter performed with a 30 mCi activity of radioiodine [5, 6], showed a better outcome of GO in patients who had undergone TTA. In a relatively recent study, we demonstrated that a 15 mCi activity of radioiodine upon rhTSH stimulation is equally effective as a 30 mCi activity in achieving thyroid ablation in patients with Graves’ hyperthyroidism following thyroidectomy, as shown by rhTSH-stimulated Tg assays [7]. Thus, here, we investigated retrospectively whether TTA performed with a 15 mCi activity of radioiodine is followed by a better outcome of GO to ivGC compared with thyroidectomy alone. Our results show that ablation performed as here is associated with a better overall outcome of GO to ivGC in the short term (24 weeks), whereas in the long term (48 weeks), ablation did not offer a substantial advantage compared with thyroidectomy alone. Our findings are in line with the previous observations in GO patients given a 30 mCi activity of radioiodine, who displayed a better GO outcome in the short [5], but not in the long term [12]. Thus, the real advantage of total thyroid ablation seems to be a more rapid response to ivGC treatment. The better outcome of GO at 24 weeks in TTA patients probably reflected a greater extent of amelioration of proptosis and diplopia, even though neither of the variables were significantly different compared with the Tx group, presumably because of the relatively small numerosity of our sample size, with a consequent, relatively low statistical power. The latter, was certainly one of the major limitations of the present study, along with its retrospective nature. Thus, prospective, possibly randomized studies in a larger number of subjects are certainly needed to confirm these preliminary findings.

**Funding** Open access funding provided by Università di Pisa within the CRUI-CARE Agreement.

**Declarations**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Informed consent** Informed consent was obtained from the individual participant included in the study.

**Ethical approval** All procedure performed in the study involving human participants were in accordance with the ethical standards of the Trust and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Being a retrospective investigation, ethical approval was not required.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Bahn RS (2015) Current Insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778
2. Nicoli F, Lanzolla G, Mantuano M, Ionnini L, Mazzoni B, Leo M, Sframeli A, Posarelli C, Maglionico MN, Figus M, Nardi M, Marcocci C, Marinò M (2020) Correlation between serum anti-TSH receptor autoantibodies and the clinical feature of Graves’ orbitopathy. J Endocrinol Invest. [in press].
3. Lanzolla G, Ricci D, Nicoli F, Sabini E, Sframeli A, Brancatella A, Mantuano M, Dottore GR, Bucci I, Figus M, Nardi M, Latrofa F, Marcocci C, Marinò M (2020) Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study. J Endocrinol Invest [in press].
4. Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Total thyroid ablation in Graves’ orbitopathy. J Endocrinol Invest 38:809–815
5. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzoni B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653–1958
6. Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturion G, Presti S, Alibrando A, Campanini A, Baldari S, Trimarchi F, Vermiglio F (2014) Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves’ orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab 99:1783–1789
7. Leo M, Sabini E, Ionnini L, Sframeli A, Mazzoni B, Menconi F, Molinaro E, Bianchi F, Brozzi F, Santini P, Elisei R, Nardi M, Vitti P, Marcocci C, Perros P, Salvi M, Wiersonga WM European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 5:9–26
8. Bartalena L, Baldteschi L, Boboridis K, Ekstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersonga WM European Group on Graves’ Orbitopathy. J Endocrinol Invest. [in press].
9. Catz B, Perzik SL (1969) Total thyroidectomy in the management of thyrotoxic and euthyroid Graves’ disease. Am J Surg 118:434–438
10. De Groot LJ, Benjouarawong Y (1996) Evaluation of thyroid ablative therapy for ophthalmopathy of Graves’ disease. Orbit 15:187–196
11. Moleti M, Mattina F, Salamone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F (2003) Effects of thyroidotomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves’ ophthalmopathy. Thyroid 13:653–658
12. Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzoni B, Sisti E, Profilo MA, Marinò M (2011) Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44–48

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.